A Korean SME, a research-oriented venture enterprise, is looking for partners to collaborate on a Eurostars2 project proposal. The project aims to develop protein or chemical compound drugs and health functional foods to prevent and treat bone destruction caused by bone metastasis from breast carcinoma or osteoporosis. The SME is seeking companies, universities, or research institutes specialized in breast cancer and protein engineering.
A Korean SME specializes in healthcare research and development. The technology of the company is guaranteed by Korea Technology Finance Corporation since 2010. The SME is planning to do research on protein drugs for suppressing bone metastasis caused by breast cancer.
The objective of the project is discovering health functional foods and biopharmaceutical materials. The health functional foods working like botanical drugs induce the spread of the protein drugs. The protein or chemical compound drugs are to prevent breast cancer proliferation and bone metastasis of breast carcinoma. These also inhibit and treat osteolytic bone resorption caused by cancer. Compared to other drugs in the market, the protein drugs from the project could reduce serious side effects remarkably
The SME is searching for universities, research institutes, and other companies that have expertise in protein engineering and breast cancer. The SME is willing to exchange information and collaborate on research and development.
Deadline for EOI: 1 February 2019
Deadline for Call: 1 March 2019
Project duration: 104 weeks
- Specific area of activity of the partner: Type and Role of Partner Sought Type of partner sought -University, R&D Institute, and SME
Specific area of activity of partner
-protein engineering professional
-breast cancer researcher
Tasks to be performed by the partner sought
-do research together on breast cancer and protein engineering
develop protein drugs and health functional food based on the research
Type and Size of Partner Sought
SME 11-50,University,R&D Institution,SME <10,251-500,SME 51-250,>500
Type of Partnership Considered Research cooperation agreement
- Suppressing proliferation and bone metastasis of breast cancer - Treating and inhibiting osteolytic bone resorption - Remarkable reduction of serious side effects